Farmacotherapy

Rol actual de los nuevos antiplaquetarios en el síndrome coronario agudo

solaci
solaci
482
0

Ramon-Corbalan

Ramón Corbalan
2011-08-03

Previous article
Evaluación de enfermedad coronaria con SPECT y PET
Next article
Therapeutic strategies for the control of dyslipemia
solaci
solaci

More articles by this author

Antiplatelet therapy advance in ACS and PCI

solaci - 0
Jorge Belardi 2011-08-05

Interruption of antiplatelet therapy for non-cardiac surgery

solaci - 0
Ajay Kirtane 2011-08-03

Protección gástrica en pacientes sometidos a angioplastia coronaria

solaci - 0
Gastón Dussaillant 2011-08-03

Therapeutic strategies for the control of dyslipemia

solaci - 0
Ada Cuevas 2011-08-03

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Farmacotherapy

Antiplatelet therapy advance in ACS and PCI

Jorge Belardi 2011-08-05
solaci -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Dr. Omar Tupayachi - 0
Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Dr. Juan Manuel Pérez - 0
Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Dr. Juan Manuel Pérez - 0
Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...